Efficacy of liraglutide in treatment obesity: in focus of the SCALE study
Cherenko M. S., Mankovskyi B. M.
Obesity is a chronic, progressive disease that is associated with increased mortality and risk of development of various diseases, primarily metabolic and cardiovascular, as well as oncological and mental diseases. The prevalence of overweight patients in the population is increasing worldwide as among adults, as well as among children, adolescents and the elderly. Liraglutide, which is actively used to treat type 2 dia- betes in a dose of 1.8 mg/day, showed high efficiency for weight loss at a dose of 3.0 mg per day. Analog glucagon-like peptide liraglutide at a dose of 3.0 mg per day is approved in the European Union, USA, Canada and Ukraine for use to reduce weight as a supplement to diet and exercise in adult patients with obesity (BMI more than 30 kg/m2) or excessive body weight (BMI from 27 to 30 kg/m2) in the presence of at least one accompanying weight-related disease, such as prediabetes or type 2 diabetes type, hypertension, dyslipidemia or obstructive sleep apnea.
Keywords: obesity, excessive body weight, mortality, glucagon-like peptide, liraglutide, weight reduction.